{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:13:10Z","timestamp":1787242390493,"version":"build-2736575974"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    This study aimed to provide real-world evidence on the characteristics, treatment patterns, and outcomes of patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) treatment in Hungary between 2011 and 2019.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients and methods:<\/jats:bold>\n                    This nationwide, retrospective study included patients who were newly diagnosed with CML in Hungarian clinical practice between January 2011 and December 2019. The analysis was based on the reimbursed prescription claims for imatinib, bosutinib, dasatinib, nilotinib, or ponatinib with the ICD-10 code C9210 in a public pharmacy between January 2009 and December 2019 using data from the National Health Insurance Fund (NHIF) of Hungary. CML incidence and prevalence, TKI treatment patterns, comorbidities, and overall survival (OS) were examined.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Between 2011 and 2019, altogether 1,407 patients were diagnosed with CML, with an annual average of 156 patients. The number of patients newly initiating first-line TKI therapy for CML significantly increased between 2011 and 2019 (2011:\n                    <jats:italic>n<\/jats:italic>\n                    = 136 vs. 2019:\n                    <jats:italic>n<\/jats:italic>\n                    = 191;\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0043). Nilotinib was typically prescribed for younger patients (\u226464\u00a0years), while older patients (\u226565\u00a0years) mostly received imatinib. The most common comorbidity of CML patients was hypertension, and the proportion of patients with other malignancies was relatively high in all treatment groups. 5-year OS was 77.1% during the whole study period. Patients initiating first-line TKI treatment for CML in 2015 had significantly better 4-year OS compared to those starting treatment in 2011 (82.4% vs. 73.5%, respectively, (HR 0.53 (95%CI 0.32\u20130.87)\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0118).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This study is the first to provide insights into the characteristics, treatment patterns, and outcomes of CML patients treated with TKIs in Hungarian clinical practice between 2011 and 2019. We found slightly lower OS rates compared to other European countries, however, there was a statistically significant improvement in 4-year OS during the study period. The management of CML was in line with international guidelines and recommendations.\n                  <\/jats:p>","DOI":"10.3389\/pore.2024.1611497","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T10:39:24Z","timestamp":1708425564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary"],"prefix":"10.3389","volume":"30","author":[{"given":"Peter","family":"Batar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyorgy","family":"Rokszin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Abonyi-Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Demeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/ejh.12695","article-title":"Chronic myeloid leukemia in The Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012","volume":"97","author":"Thielen","year":"2016","journal-title":"Eur J Haematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"357027","DOI":"10.1155\/2014\/357027","article-title":"Imatinib: a breakthrough of targeted therapy in cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother Res Pract"},{"key":"B4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000501537","article-title":"Systematic review and meta-analysis of -New-Generation tyrosine kinase inhibitors versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"143","author":"Pan","year":"2020","journal-title":"Acta Haematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.clinthera.2018.12.013","article-title":"The case for real-world evidence in the future of clinical research on chronic myeloid leukemia","volume":"41","author":"Webster","year":"2019","journal-title":"Clin Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/ajh.24887","article-title":"First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY","volume":"92","author":"Goldberg","year":"2017","journal-title":"Am J Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/leu.2013.171","article-title":"The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib","volume":"27","author":"Hoffmann","year":"2013","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study","volume":"165","author":"Dahl\u00e9n","year":"2016","journal-title":"Ann Intern Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1185\/03007995.2016.1140030","article-title":"Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy","volume":"32","author":"Smith","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3324\/haematol.2017.174953","article-title":"Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia","volume":"102","author":"Geelen","year":"2017","journal-title":"Haematologica"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","article-title":"Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry","volume":"122","author":"H\u00f6glund","year":"2013","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/ejh.12743","article-title":"Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence","volume":"97","author":"Gunnarsson","year":"2016","journal-title":"Eur J Haematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12885-016-2238-9","article-title":"Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013","volume":"16","author":"Beinortas","year":"2016","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ajh.24591","article-title":"A population-based study of chronic myeloid leukemia patients treated with imatinib in first line","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am J Hematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","article-title":"Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV","volume":"126","author":"Saussele","year":"2015","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.seminhematol.2010.07.001","article-title":"Chronic myeloid leukemia: a historical perspective","volume":"47","author":"Goldman","year":"2010","journal-title":"Semin Hematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","volume":"2009","author":"Bixby","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2040620719826444","DOI":"10.1177\/2040620719826444","article-title":"Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia","volume":"10","author":"Molica","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-137393","article-title":"Bosutinib (BOS) versus imatinib for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML): final 5-year results from the bfore trial","author":"Br\u00fcmmendorf","year":"2020"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1111\/cas.14580","article-title":"Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor","volume":"111","author":"Ono","year":"2020","journal-title":"Cancer Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.clml.2015.09.008","article-title":"Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on national comprehensive network treatment guidelines","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/hematology.2020006911","article-title":"How to manage CML patients with comorbidities","volume":"2020","author":"Cortes","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3324\/haematol.2011.041251","article-title":"Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib","volume":"96","author":"Breccia","year":"2011","journal-title":"Haematologica"},{"key":"B38","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"key":"B39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.clml.2018.12.004","article-title":"Cardiovascular risk and cardiovascular events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"19","author":"Assun\u00e7\u00e3o","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B41","volume-title":"Studying first line treatment of chronic myeloid leukemia (CML) in a real-world setting (SIMPLICITY)","year":"2022"},{"key":"B42","first-page":"152","volume-title":"Global report on hypertension: the race against a silent killer","year":"2023"},{"key":"B43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B44","doi-asserted-by":"publisher","first-page":"739171","DOI":"10.3389\/fonc.2021.739171","article-title":"Prognostic factors for overall survival in chronic myeloid leukemia patients: a multicentric cohort study by the Italian CML GIMEMA network","volume":"11","author":"Specchia","year":"2021","journal-title":"Front Oncol"}],"updated-by":[{"DOI":"10.3389\/pore.2024.1611758","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000}}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2024.1611497\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T08:00:50Z","timestamp":1710921650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2024.1611497\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":44,"alternative-id":["10.3389\/pore.2024.1611497"],"URL":"https:\/\/doi.org\/10.3389\/pore.2024.1611497","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"article-number":"1611497"}}